EA202190106A1 - Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройств - Google Patents
Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройствInfo
- Publication number
- EA202190106A1 EA202190106A1 EA202190106A EA202190106A EA202190106A1 EA 202190106 A1 EA202190106 A1 EA 202190106A1 EA 202190106 A EA202190106 A EA 202190106A EA 202190106 A EA202190106 A EA 202190106A EA 202190106 A1 EA202190106 A1 EA 202190106A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- compositions
- treatment
- masp
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
В одном из аспектов изобретение относится к композициям и способам профилактики, уменьшения и/или лечения заболевания, расстройства или состояния, ассоциированного с индуцированной фибрином активацией системы комплемента и связанной с ней активацией системы коагуляции и/или контактной системы, включающим нуждающегося в этом субъекту введение терапевтического количества антитела, ингибирующего MASP-2. В некоторых вариантах осуществления способы по изобретению обеспечивают антикоагуляцию и/или антитромбоз и/или предотвращают тромбообразование, не влияя на гемостаз. В одном из вариантов осуществления этого аспекта изобретения композиции и способы применимы для лечения субъекта, страдающего или подверженного риску развития заболевания, расстройства или состояния, ассоциированного с воспалением, связанным с комплементом, чрезмерной активацией системы коагуляции или контактной системы, инициированной фибрином или активированными тромбоцитами.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862688611P | 2018-06-22 | 2018-06-22 | |
PCT/US2019/038188 WO2019246367A1 (en) | 2018-06-22 | 2019-06-20 | Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202190106A1 true EA202190106A1 (ru) | 2021-04-13 |
Family
ID=68984236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202190106A EA202190106A1 (ru) | 2018-06-22 | 2019-06-20 | Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройств |
Country Status (17)
Country | Link |
---|---|
US (2) | US20200140570A1 (ru) |
EP (1) | EP3836965A4 (ru) |
JP (1) | JP2021527698A (ru) |
KR (1) | KR20210024003A (ru) |
CN (1) | CN112638417A (ru) |
AU (1) | AU2019288459A1 (ru) |
BR (1) | BR112020025841A2 (ru) |
CA (1) | CA3104083A1 (ru) |
CL (1) | CL2020003324A1 (ru) |
EA (1) | EA202190106A1 (ru) |
IL (1) | IL279588A (ru) |
JO (1) | JOP20200328A1 (ru) |
MA (1) | MA53234A (ru) |
MX (1) | MX2020013755A (ru) |
PH (1) | PH12020552188A1 (ru) |
SG (1) | SG11202012627UA (ru) |
WO (1) | WO2019246367A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114634575A (zh) * | 2020-12-16 | 2022-06-17 | 康诺亚生物医药科技(成都)有限公司 | 一种补体抑制剂的开发和应用 |
CA3206789A1 (en) * | 2021-02-05 | 2022-08-11 | Gregory A. Demopulos | Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19 |
BR112023025596A2 (pt) * | 2021-06-08 | 2024-02-27 | Jiangxi Jemincare Group Co Ltd | Anticorpo anti-masp-2 e uso do mesmo |
CN116615544A (zh) * | 2021-12-10 | 2023-08-18 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别masp2的抗体及其应用 |
WO2023173036A2 (en) * | 2022-03-10 | 2023-09-14 | Omeros Corporation | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004216176B2 (en) * | 2003-02-21 | 2008-04-03 | Genentech, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
EP2374819B1 (en) * | 2003-05-12 | 2017-03-22 | Helion Biotech ApS | Antibodies to MASP-2 |
EP3530288A3 (en) * | 2004-06-10 | 2019-12-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20140056873A1 (en) * | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
EP1810979B1 (en) * | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
US20150166676A1 (en) * | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
BR112014031522A2 (pt) * | 2012-06-18 | 2017-08-01 | Omeros Corp | métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento |
EP3057993B1 (en) * | 2013-10-17 | 2020-08-12 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US20150353623A1 (en) * | 2014-04-03 | 2015-12-10 | Loma Linda University | Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases |
KR102432062B1 (ko) * | 2015-11-09 | 2022-08-12 | 오메로스 코포레이션 | Masp-2 의존성 보체 활성화와 관련된 질병의 치료 방법 |
-
2019
- 2019-06-20 EP EP19823617.6A patent/EP3836965A4/en active Pending
- 2019-06-20 BR BR112020025841-5A patent/BR112020025841A2/pt unknown
- 2019-06-20 MA MA053234A patent/MA53234A/fr unknown
- 2019-06-20 MX MX2020013755A patent/MX2020013755A/es unknown
- 2019-06-20 AU AU2019288459A patent/AU2019288459A1/en active Pending
- 2019-06-20 JP JP2020571365A patent/JP2021527698A/ja active Pending
- 2019-06-20 CN CN201980041741.5A patent/CN112638417A/zh active Pending
- 2019-06-20 EA EA202190106A patent/EA202190106A1/ru unknown
- 2019-06-20 SG SG11202012627UA patent/SG11202012627UA/en unknown
- 2019-06-20 CA CA3104083A patent/CA3104083A1/en active Pending
- 2019-06-20 JO JOP/2020/0328A patent/JOP20200328A1/ar unknown
- 2019-06-20 US US16/447,085 patent/US20200140570A1/en not_active Abandoned
- 2019-06-20 WO PCT/US2019/038188 patent/WO2019246367A1/en unknown
- 2019-06-20 KR KR1020217001375A patent/KR20210024003A/ko unknown
-
2020
- 2020-12-16 PH PH12020552188A patent/PH12020552188A1/en unknown
- 2020-12-20 IL IL279588A patent/IL279588A/en unknown
- 2020-12-21 CL CL2020003324A patent/CL2020003324A1/es unknown
-
2022
- 2022-11-03 US US18/052,371 patent/US20230212314A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019288459A2 (en) | 2021-03-18 |
MX2020013755A (es) | 2021-05-12 |
IL279588A (en) | 2021-03-01 |
WO2019246367A1 (en) | 2019-12-26 |
KR20210024003A (ko) | 2021-03-04 |
US20200140570A1 (en) | 2020-05-07 |
PH12020552188A1 (en) | 2021-06-28 |
AU2019288459A1 (en) | 2021-02-04 |
SG11202012627UA (en) | 2021-01-28 |
BR112020025841A2 (pt) | 2021-03-23 |
CN112638417A (zh) | 2021-04-09 |
EP3836965A1 (en) | 2021-06-23 |
MA53234A (fr) | 2022-04-20 |
US20230212314A1 (en) | 2023-07-06 |
JP2021527698A (ja) | 2021-10-14 |
CL2020003324A1 (es) | 2021-04-23 |
EP3836965A4 (en) | 2022-04-20 |
JOP20200328A1 (ar) | 2020-12-15 |
CA3104083A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202190106A1 (ru) | Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройств | |
EA202191185A1 (ru) | Способы ингибирования ангиогенеза у пациента | |
CY1124902T1 (el) | Μεθοδοι αντιμετωπισης της υπερλιπιδημιας με αναστολεα angptl8 και αναστολεα angptl3 | |
EA202091965A1 (ru) | КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 ИЛИ ДВОЙНОГО ИНГИБИТОРА Bcl-2/Bcl-xL И ИНГИБИТОРА BTK И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
BR112018013723A2 (pt) | métodos para tratar, inibir, aliviar ou prevenir fibrose, para prevenir ou reduzir danos renais, para inibir progressão da doença renal crônica, para proteger um rim de lesão renal e para tratar um indivíduo humano que sofre de nefropatia por imunoglobulina a (igan) e que sofre de nefropatia membranosa (mn). | |
EA201890394A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ | |
PE20180556A1 (es) | Anticuerpos inhibidores via del factor tisular y usos de los mismos | |
EA200700333A1 (ru) | Терапевтические применения ингибиторов rtp801 | |
WO2010065077A3 (en) | Antagonists of il-6 to prevent or treat thrombosis | |
CL2019003789A1 (es) | Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1. | |
EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
EA202192625A1 (ru) | Лиганды псевдокиназы tyk2 | |
EA202191764A1 (ru) | Замещенные оксопиридиновые производные | |
EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
EA201991650A1 (ru) | Способы лечения неврологических расстройств | |
EA202193038A1 (ru) | Антитела против sema3a и их применения для лечения заболеваний глаз | |
EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
EA202191358A1 (ru) | Новые соединения и их применение в лечении | |
MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation | |
CY1126054T1 (el) | Πεπτιδια για θεραπεια και αποτροπη διαβητη και συναφων διαταραχων | |
WO2019165158A8 (en) | Il-6 inhibitors and methods of treatment | |
EA201692155A1 (ru) | МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
CL2019003485A1 (es) | Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909) | |
MX2018010401A (es) | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. |